A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Industry sponsor intelligence
Novo NordiskClinical Pipeline.
Lead-sponsor view of Novo Nordisk's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 96
- Recruiting
- 23
- Active
- 22
- Completed
- 49
- Results posted
- 12
- Avg enrollment
- 479
Pipeline overview
Programs by phase and activity.
Velocity
Novo Nordisk trials by start year
Study start year · indexed snapshot
Development
Trials by phase
86phase labels
Early Phase 10
Phase 135
Phase 211
Phase 337
Phase 43
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Liraglutide → | 6 | 1 | 0 | 1 | 1 | 2 |
| Dulaglutide → | 2 | 0 | 0 | 0 | 1 | 1 |
| Lixisenatide → | 1 | 0 | 0 | 0 | 1 | 0 |
| Cagrilintide → | 42 | 17 | 5 | 20 | 0 | 19 |
| Amycretin → | 21 | 10 | 2 | 9 | 0 | 12 |
| Somapacitan → | 20 | 7 | 2 | 7 | 0 | 7 |
| Semaglutide → | 14 | 1 | 3 | 8 | 0 | 10 |
| Glucagon → | 3 | 1 | 0 | 2 | 0 | 2 |
| Tirzepatide → | 1 | 0 | 0 | 1 | 0 | 0 |
| Exenatide → | 1 | 0 | 0 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
609
2026-07
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
Novo Nordisk · Pregnancy · Obesity
Not applicable
Enrolling by invitation
2,701
2026-07
Phase 1
Recruiting
71
2026-07
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
3,400
2026-07
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk · Cardiovascular Disease
Phase 3
Active, not recruiting
7,101
2026-07
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk · Overweight · Obesity
Phase 3
Recruiting
460
2026-07
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk · Obesity · Heart Failure
Phase 3
Recruiting
5,610
2026-07
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 2
Recruiting
300
2026-07
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
Showing 10 of 45 studies
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 3
Completed
1,023
2026-07
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk · Type 2 Diabetes Mellitus
Phase 3
Completed
2,734
2026-07
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Novo Nordisk · Growth Hormone Deficiency in Children
Phase 3
Completed
200
2026-05
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Novo Nordisk · Obesity
Phase 1
Completed
34
2026-05
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Novo Nordisk · Obesity
Phase 3
Completed
300
2026-05
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk · Type 2 Diabetes
Phase 3
Completed
1,024
2026-04
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
Novo Nordisk · Obesity
Not applicable
Completed
27
2026-04
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk · Type 2 Diabetes
Phase 3
Completed
189
2026-04
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Novo Nordisk · Chronic Kidney Disease · Type 2 Diabetes
Phase 2
Completed
626
2026-04
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Novo Nordisk · Alcohol-related Liver Disease
Phase 2
Completed
270
2026-03
Showing 10 of 49 studies
Search sponsor records
All Novo Nordisk studies.
This page groups studies where Novo Nordisk is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
96 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightJul 30, 2026NCT07011667A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termJul 24, 2026NCT05503927A Study to Evaluate the Safety of Exposure to Wegovy During PregnancyJul 21, 2026NCT07225816Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)Jul 21, 2026NCT05567796A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightJul 17, 2026NCT05669755REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsJul 17, 2026NCT06534411A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothJul 17, 2026NCT07253285A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightJul 17, 2026NCT07567001A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityJul 15, 2026NCT07668388A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesJul 14, 2026